人人干人人摸人人骑-人人干人人澡-人人干天天搞夜夜爽-人人干综合-人人搞人人摸-人人搞人人模

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 久久久久人妻精品区一三寸果冻 | 九七影视app官方版下载 | 在线观看精品国产 | 蜜桃网中文字幕 | 熟女无码| 无码av免费一区二区三区 | 国产欧美日韩精品在 | 97久久超碰成人精品网页 | 久久婷婷国产麻豆91 | 国产三级在线电影 | 不卡的国产高清无码视频 | 91免费网| 日产无人区A片在线观看 | av最新网站| 国产成人久久av免费看澳门 | 亚洲AV网成人 | 深夜A级毛片手机免费看 | 激情五月激情电影在线观看 | 日韩专区欧美激情 | 欧美三级在线看 | 国产日韩精品1区2区3区 | 成人AV专区 | 蜜臀91精品国产高清 | 国产一区中文字幕 | 国产一级免费精品视频 | 亚洲熟妇无码一区二区三区导航 | 中文无码熟妇人妻 | 91精品最新国产在线 | 国语对白在线播放视频 | 国产三级日本三级日产三级66 | 国产男女猛烈无遮挡a片 | 欧美在线视 | 国产精品亚洲欧美高清 | 精品欧美中文在线观看 | 激情午夜成人影院无码在线 | 嗯啊啊国产视频 | 久久性AV| 成全在线观看免费高清动漫 | 亚洲成人电影一区 | 精品国产又粗又大又黄又硬 | 精品无码久久久久久久久果冻 |